Intravitreal toxicity of moxifloxacin

Retina

Volumn 26, Issue 2, 2006, Pages 187-190

  Aydin, Erdinc ^a   Kazi, Abdul Ahad ^a,b   Peyman, Gholam A ^a   Esfahani, Mohammad Riazi ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b LIAQUAT UNIVERSITY OF MEDICAL AND HEALTH SCIENCES   (Pakistan)

Author keywords

Endophthalmitis; Fluoroquinolone; Intravitreal injection; Moxifloxacin; Retinal toxicity

Indexed keywords

GLUCOSE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; EYE DROPS; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DOSE RESPONSE; ELECTROPHYSIOLOGY; ELECTRORETINOGRAPHY; ENUCLEATION; EYE TOXICITY; HISTOPATHOLOGY; MICROSCOPY; NONHUMAN; OPHTHALMOSCOPY; RABBIT; RETINA; SLIT LAMP; TITRIMETRY; ANIMAL; DRUG EFFECT; DRUG SCREENING; INJECTION; PATHOPHYSIOLOGY; VITREOUS BODY;

ANIMALS; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; DRUG EVALUATION, PRECLINICAL; ELECTRORETINOGRAPHY; INJECTIONS; OPHTHALMIC SOLUTIONS; OPHTHALMOSCOPY; QUINOLINES; RABBITS; RETINA; VITREOUS BODY;

EID: 33645733585     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006982-200602000-00011     Document Type: Article

References (21)

1. Aaberg TM Jr, Flynn HW Jr, Schiffman J, Newton J. Nosocomial acute-onset postoperative endophthalmitis survey. A 10-year review of incidence and outcomes. Ophthalmology 1998;105:1004-1010.
2. Javitt JC, Street DA, Tielsch JM, et al. National outcomes of cataract extraction. Retinal detachment and endophthalmitis after outpatient cataract surgery. Cataract Patient Outcome Research Team. Ophthalmology 1994;101:100-106.
3. Peyman GA. Antibiotic administration in the treatment of bacterial endophthalmitis. II. Intravitreal injections. Surv Ophthalmol 1977; 21:332, 339-346.
4. Flynn HW, Pulido JS, Pflugfelder SC, et al. Endophthalmitis therapy: changing antibiotic sensitivity patterns and current therapeutic recommendations. Arch Ophthalmol 1991;109:175-176. [Erratum appears in Arch Ophthalmol 1991;109:615.]
5. Homer P, Peyman GA, Koziol J, Sanders DR. Intravitreal injection of vancomycin in experimental staphylococcal endophthalmitis. Acta Ophthalmol (Copenh) 1975;53:311-320.
6. Smith A, Pennefather PM, Kaye SB, Hart CA. Fluoroquinolones: place in ocular therapy. Drugs 2001;61:747-761.
7. Leibowitz HM. Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis. Am J Ophthalmol 1991;112:S34-S47.
8. O'Brien TP, Maguire MG, Fink NE, et al. Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis. Report from the Bacterial Keratitis Study Research Group. Arch Ophthalmol 1995;113:1257-1265.
9. Leeming JP. Treatment of ocular infections with topical antibacterials. Clin Pharmacokinet 1999;37:351-360.
10. Kowalski RP, Karenchak LM, Gordon YJ. Comparison of ciprofloxacin and ofloxacin using human corneal susceptibility levels. Cornea 1998;17:282-287.
11. Streilein JW. Immunoregulatory mechanisms of the eye. Prog Retin Eye Res 1999;18:357-370.
12. O'Day DM, Jones DB, Patrinely J, Elliott JH. Staphylococcus epidermidis endophthalmitis. Visual outcome following noninvasive therapy. Ophthalmology 1982;89:354-360.
13. The Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol 1995;113:1479-1496.
14. Peyman GA, Schulman JA. Intravitreal drug therapy. Jpn J Ophthalmol 1989;33:392-404.
15. Johnson MW, Doft BH, Kelsey SF, et al. The Endophthalmitis Vitrectomy Study. Relationship between clinical presentation and microbiologic spectrum. Ophthalmology 1997;104:261-272.
16. Hwang DG. Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones. Surv Ophthalmol 2004;49:S79-S83.
17. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: a five-year review. Ophthalmology 1999;106:1313-1318.
18. Mather R, Karenchak LM, Romanowski EG, Kowalski RP. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol 2002;133:463-466.
19. Domagala JM. Structure-activity and structure-side-effect relationships for the quinolone antibacterial. J Antimicrob Chem 1994;33:685-706.
20. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis 2001;33:S147-S156.
21. Drlica K. A strategy for fighting antibiotic resistance. ASM News 2001;67:27-33.